Kaat Bollaerts is a PhD-level biostatistician with over 20 years of experience in vaccine and infectious disease epidemiology. At P95, Kaat leads the Epidemiology Business Unit, overseeing business development, strategic direction and the delivery of high-quality Real World Evidence research for global clients, including pharmaceutical companies, governments, and public health institutions. Her work combines scientific expertise with practical insight to support post-authorization studies, vaccine impact assessments, and public health decision-making.

Kaat serves as Principal Investigator of COVIDRIVE/id.DRIVE (https://iddrive.eu/), a global public-private partnership generating Real World Evidence on infectious diseases and vaccine effectiveness. Kaat also contributes to international teaching programs on vaccine evaluation and co-authored the open access book Vaccination Programmes: Epidemiology, Monitoring, and Evaluation (https://doi.org/10.4324/9781315166414), a foundational resource for professionals in immunization program monitoring and policy.